AUTHORS
Aung M. Tun, MD, Melissa Larson, MS2, Anita Kumar, MD3, Ashlee Joseph, BS4, David Bond, MD, BS5, Kami Maddocks, MD6, Steven Hwang, MD, BS7, Drew Gerber, MD8, Zoey Harris, MD9, Javier L. Munoz, MD, MBA10, Taylor R. Brooks, MD11, Brian Hill, MD, PhD12, Diego Villa, MD13, Laveniya Kugathasan14, Arash Velayati, MD, MBA15, Brian Greenwell16, Jia Ruan, MD, PhD17, Rahul S Bhansali, MD18, Stefan K Barta, MD19, Philip Young20, Craig Portell21, Alexey V. Danilov, MD, PhD22, Tycel Phillips, MD, FASCO23, Christine Ryan, MD24, Reid W Merryman, MD25, Anthony Stack, DO26, Marcus Messmer, MD27, Sabarish Ayyappan, MD28, Eric Mou, MD29, Georgios N Pongas30, Izidore S. Lossos, M.D.31, Imran Ahmed Nizamuddin, MD32, Brad S. Kahl, MD33, Lauren G. Banaszak, MD34, Priyanka A. Pophali, MD35, Alexander Stanisic, BS36, Reem Karmali, MD37, Preetesh Jain, MBBS, MD, DM, PhD38, Michael Wang, MD39, Manali Kamdar, MD40, Jacob Anna41, Patrick M Reagan, MD42, Natalie S Grover, MD43, Nazneen Khan44, Evguenia Bhurtel, MD45, Firas Baidoun46, Muhamad Alhaj Moustafa, MD, MS47, Mayur Narkhede, MD48, Amitkumar Mehta49, Tamara K Moyo, MD,PhD50, Nilanjan Ghosh, MD51, Matthew J. Maurer, Sc.D., M.S.52, James R. Cerhan, MD, PhD53, Peter Martin, FRCPC, MD, MS54, Jonathon B. Cohen, MD, MS55, Yucai Wang, MD, PhD56
AFFILIATIONS
1 University of Kansas Cancer Center, Kansas City, KS, USA, Westwood, Kansas, United States
2 Mayo Clinic, Rochester, Rochester, Minnesota, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Memorial Sloan Kettering Cancer Center, New York, New York, United States
5 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
6 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
7 Mayo Clinic, Rochester, Rochester, Minnesota, United States
8 Emory University, Atlanta, Georgia
9 Mayo Clinic, Phonenix, Arizona, United States
10 Mayo Clinic, Phonenix, Arizona, United States
11 Cleveland Clinic, Cleveland, Ohio, United States
12 Cleveland Clinic, Cleveland, Ohio, United States
13 BC Cancer Agency, Vancouver, Canada
14 BC Cancer Agency, Vancouver, Canada
15 Medical University of South Carolina, Charleston, United States
16 Medical University of South Carolina, Charleston, United States
17 Weill Cornell Medicine, New York, United States
18 University of Pennsylvania, Philadelphia, United States
19 University of Pennsylvania, Philadelphia, United States
20 University of Virginia, Charlottesville, United States
21 University of Virginia, Charlottesville, United States
22 City of Hope, Duarte, United States
23 City of Hope, Duarte, United States
24 Dana Farber Cancer Institute, Boston, United States
25 Dana Farber Cancer Institute, Boston, United States
26 Fox Chase Cancer Center, Philadelphia, United States
27 Fox Chase Cancer Center, Philadelphia, United States
28 University of Iowa, Iowa City, United States
29 University of Iowa, Iowa City, United States
30 University of Miami, Miami, United States
31 University of Miami, Miami, United States
32 Washington University, St. Louis, United States
33 Washington University, St. Louis, United States
34 University of Wisconsin, Madison, United States
35 University of Wisconsin, Madison, United States
36 Northwestern University, Chicago, United States
37 Northwestern University, Chicago, United States
38 MD Anderson Cancer Center, Houston, United States
39 MD Anderson Cancer Center, Houston, United States
40 University of Colorado, Aurora, United States
41 University of Colorado, Aurora, United States
42 University of Rochester, Rochester, United States
43 University of North Carolina, Chapel Hill, United States
44 University of North Carolina, Chapel Hill, United States
45 University of Kansas Cancer Center, Kansas City, KS, USA, Westwood, Kansas, United States
46 Mayo Clinic, Jacksonville, United States
47 Mayo Clinic, Jacksonville, United States
48 University of Alabama, Birmingham, United States
49 University of Alabama, Birmingham, United States
50 Atrium Health Levine Cancer Institute, Charlotte, United States
51 Atrium Health Levine Cancer Institute, Charlotte, United States
52 Mayo Clinic, Rochester, Rochester, Minnesota, United States
53 Mayo Clinic, Rochester, Rochester, Minnesota, United States
54 NYU Langone, New York, United States, Weill Cornell Medicine, New York, United States
55 Emory University, Atlanta, Georgia
56 Mayo Clinic, Rochester, Rochester, Minnesota, United States
ABSTRACT
Introduction: TP53 aberration (aberr) is a significant risk factor in mantle cell lymphoma (MCL) treated with chemoimmunotherapy. While the adverse prognostic impact of TP53 mutation (mut) is well established, the prognostic significance of TP53 deletion (del) remains uncertain. We sought to study the impact of TP53 aberr in a large cohort of patients (pts) treated with first-line (1L) bendamustine-rituximab (BR) across 27 centers.
Methods: Adult pts with MCL and available TP53 data treated with 1L BR (+/- rituximab maintenance; no stem cell transplant) between 2007 and 2020 were included. Baseline characteristics, treatment, and follow-up data were abstracted. Event-free survival (EFS) was defined as time from treatment to progression, relapse, retreatment, or death. Overall survival (OS) was defined as time from treatment to death.
Results: 319 pts were included. Median age was 71 years (IQR 65–75), and 225 (71%) were male. 41 (14%) pts had ECOG PS ≥2; 300 (96%) had stage III-IV disease; and simplified MIPI (sMIPI) was low risk in 66 (21%), intermediate in 106 (33%), and high in 147 (46%) pts.
78 (25%) pts had TP53 aberr (mut+ and/or del+), 119 (37%) had TP53 wild type (WT; mut−/del−) and 122 (39%) were unconfirmed negative (TP53 mut−/del-unknown [delunk] or TP53 mut-unknown [mutunk]/del−). Compared with TP53 WT group, TP53 aberr group had more pts with high-risk sMIPI (70% vs 48%), blastoid or pleomorphic morphology (38% vs11%), and complex karyotype (41% vs 15%); no statistical difference in age, sex, ECOG PS, stage, and Ki-67 was observed.
Median follow-up was 60.5 months (m). Compared with TP53 WT group, TP53 aberr group had a lower overall response rate (ORR, 79% vs 95%). Outcomes were also inferior in TP53 aberr group, with median EFS of 8.5 m (95% CI 5.6–19.1) vs 31.7 m (95% CI 26.0–43.7)(P<0.001) and median OS of 42.5 m (95% CI 29.9–57.9) vs 81.2 m (95% CI 55.0–NR)(P<0.001). Of note, unconfirmed negative groups (TP53 mut−/delunk or TP53 mutunk/del−) had ORR, EFS, and OS comparable to those with TP53 WT.
Of 195 pts with known TP53 mut status, 41 (21%) were TP53 mut+ and 154 (79%) were TP53 mut−. TP53 mut+ group had more pts with ECOG PS ≥2 (30% vs 13%), high-risk sMIPI (66% vs 39%), higher Ki-67 (≥30%; 83% vs 56%), blastoid or pleomorphic morphology (54% vs 11%), and complex karyotype (35% vs 17%), with no significant difference in age, sex, and stage. ORR was inferior in TP53 mut+ group (74% vs 94%). EFS and OS were also inferior in TP53 mut+ group, with median EFS of 5.7 m (95% CI 3.6–12.4) vs 32.9 m (95% CI 26.4 vs 45.8) (HR 2.7, 95% CI 1.7–4.2; P<0.001) and median OS of 29.9 m (95% CI 11.0–57.9) vs 100.2 m (95% CI 65.0–NR) (HR 3.3, 95% CI 2.3–5.0, P<0.001).
Of 281 pts with known TP53 del status, 55 (20%) were TP53 del+ and 226 (80%) were TP53 del−. More pts had high-risk sMIPI (73% vs 51%), blastoid or pleomorphic morphology (27% vs 13%), and complex karyotype (50% vs 18%) in the TP53 del+ group, with no statistical difference in age, sex, ECOG PS, stage, and Ki-67. ORR was inferior in TP53 del+ group (78% vs 94%). TP53 del+ group also had inferior EFS and OS, with median EFS of 9.3 m (95% CI 5.1–29.0) vs 33.5 m (95% CI 28.7 vs 41.7; HR 2.0, 95% CI 1.5–2.9; P<0.001) and median OS of 42.5 m (95% CI 30.8–NR) vs 72.8 m (95% CI 56.7–106.3; HR, 1.7; 95% CI 1.1–2.5; P=0.01).
We then compared known double positive (mut+/del+) with known single positive (mut+ or del+) in pts with TP53 aberr. 18 (23%) were mut+/del+; 23 (30%) were TP53 mut+/del−/unk; and 37 (47%) were TP53 mut−/unk/del+. TP53 mut+/del+ group was slightly older (median 73.5 vs 70–71), whereas TP53 mut+/del−/unk group had fewer pts with complex karyotype (13% vs 47–57%), and TP53 mut−/unk/del+ group had fewer pts with blastoid or pleomorphic morphology (15% vs 15-47%). There was no difference in sex, stage, sMIPI, Ki-67, and ORR among the 3 groups. Median EFS was 3.0 m (95% CI 1.9–25.3) vs 7.2 m (95% CI 5.4–27.1) vs 19.9 m (95% CI 7.8–47.6)(HR, 1.7-2.7; P=0.008) in TP53 mut+/del+ vs TP53 mut+/del−/unk vs TP53 mut−/unk/del+ groups. The corresponding median OS was 30.8 m (95% CI 6.9–NR) vs 29.9 m (95% CI 25.9–NR) vs 47.6 m (95% CI 31.8–NR)(HR, 1.2-1.9; P=0.2).
Conclusions: TP53 aberr is a strong prognostic factor for poor EFS and OS in MCL following 1L BR. Pts with TP53 mut appear to have worse outcomes than those with TP53 del, though these findings require validation in other cohorts. Upfront use of novel agents should be considered in pts with TP53 aberr.
DISCLOSURES
Aung M. Tun, MD: Curio Science - Honoraria; Acrotech - Consultancy (Includes expert testimony); KUMC - Current Employment